SPRY

New CEO Don Casale outlined three core strategic priorities for the company's next growth phase:

• Targeted Provider Commercial Execution

• Shift commercial strategy from broad consumer advertising to focused engagement with high-volume healthcare providers, which delivers higher conversion in NEPI's prevention-based anaphylaxis rescue market
• Completed expansion of the field sales organization, which will focus on the highest value prescribers representing 44% of total market opportunity
• Hired Meg Smith, a 25-year commercial executive, as new Chief Commercial Officer to lead the revised go-to-market strategy
• NEPI currently holds 8% market share in targeted provider territories versus just 1% in non-targeted areas, confirming the impact of field engagement
• Will continue working to expand commercial and Medicaid formulary coverage, but prioritizes building provider conviction to convert coverage into prescriptions

• Financial Discipline and Cost Optimization

• Implemented a rigorous cost optimization framework to reduce SG&A expense and build a clear path to cash flow breakeven for the NEPI franchise
• Ended Q2 2026 with $143.8 billion in cash, cash equivalents, and short-term investments

• Pipeline Expansion

• Extend the company's intranasal FNF platform into the chronic spontaneous urticaria (CSU) market, where there are no currently FDA-approved on-demand treatments for acute flares, creating a large unmet need opportunity
• Leverage existing commercial infrastructure and overlapping prescriber base to position CSU as a high-margin incremental growth opportunity
• Completed enrollment for the Phase IIb CSU trial; the data readout timeline shifted to Q1 2027 from the prior target of end of 2026 due to the trial's requirement for patients to log three separate acute flare episodes, which requires additional real-world data collection time

• Aggregate SG&A and R&D expenses for the second half of 2026 are guided to a range of $114 million to $126 million, including $14 million to $16 million in stock-based compensation
• Total cash-based SG&A and R&D expenses for H2 2026 are expected to be between $100 million and $110 million, representing a more than 40% reduction in cash-based SG&A expenses compared to the first half of 2026
• The reduced spending trend is expected to continue through all of 2027
• Gross margins are expected to improve over time, with clearer improvement expected as manufacturing scales and streamlines in 2027
• Management maintains a target of achieving cash flow breakeven by the end of 2027
• Management expects steady, sequential quarterly market share gains for NEPI rather than an immediate overnight spike in growth

ARS Pharma's total second quarter 2026 revenue was $33.7 million, which combines net product revenue, collaboration revenue, and supply revenue. The core NEPI product segment generated U.S. net product revenue of $26.2 million, accounting for 77.75% of total quarterly revenue. NEPI achieved a total U.S. market share of 5%, doubling year-over-year from 2.5% in Q2 2025. Within the field sales targeted prescriber universe, NEPI's market share reached 8%, up from 4% in the prior year quarter. The number of unique NEPI prescribers grew three-fold year-over-year to over 16,000 in Q2 2026. Gross margin for Q2 2026 was 62%, and 64% year-to-date. Cost of goods sold for the quarter was $12.8 million, and total operating expenses were $95.1 million, with SG&A expense totaling $77.6 million.

• Changing long-entrenched provider prescribing habits favoring traditional needle-based auto-injectors is a gradual process that requires repeated, high-quality engagement, creating execution risk for the new commercial strategy
• Broad-based consumer advertising in the prevention-based anaphylaxis market has high costs and relatively low conversion to prescriptions, which has pressured historical profitability
• Revenue and gross-to-net can vary quarter-to-quarter based on segment mix, creating near-term earnings volatility
• The CSU Phase IIb trial data readout has already been delayed by one quarter due to required real-world patient data collection, with potential for additional future delays in clinical development

Q: The analyst asks for an update on Q2 gross-to-net trends, higher cost of goods/gross margin, and plans to grow the 8% market share in targeted provider accounts beyond current levels. / A: Management states gross-to-net is currently around 50%, which is sufficient to meet profitability and cash flow breakeven targets, even with expected quarterly fluctuations. Gross margin came in at 62% for Q2 due to temporary manufacturing inefficiencies, short-dated product reserves, and pipeline launch costs; management expects gross margin to improve as production scales and streamlines in 2027. For market share growth, the now fully deployed sales team will execute repeated, evolving messaging to providers and office staff to drive sustained share gains through consistent, provider-by-provider execution.

Q: The analyst asks about payer access progression, the importance of securing Caremark formulary placement in the next cycle, and details of the revised DTC strategy. / A: Management confirms payer access is a critical first step, and currently holds 90% commercial coverage with 57% of coverage requiring no prior authorization. The core priority of the new strategy is building provider conviction rather than just expanding coverage, as coverage does not convert to prescriptions without prescriber buy-in. For DTC, the company is shifting completely away from expensive broad-based linear TV advertising to targeted, efficient spend on social media and search, which delivers higher conversion and enabled the 40% H2 2026 SG&A reduction.

Q: The analyst asks what core provider habits the new strategy aims to change, and what education detailing the new field force will implement. / A: Management explains the core entrenched habit is decades-long prescriber preference for traditional needle-based auto-injectors, where providers default to existing products without considering the risks and patient barriers to needle-based rescue therapy. The field force will focus on repeated, frequent engagement to get providers to stop and recognize the unmet clinical gap NEPI fills, which will drive gradual adoption quarter over quarter, rather than rapid growth.

Q: The analyst asks what non-revenue engagement metrics management will use to track strategy progress, and for details on the July IP license agreement for worldwide rights. / A: Management notes scripts and market share remain the primary core metrics, which will be reported quarterly for both total and targeted market segments. Interim operational metrics tracked will include call frequency and engagement activity across the entire provider office (physicians, nurses, and administrative staff), which aligns with the strategy of repeated high-quality interactions. For the new IP license, management confirms it is an early-stage opportunity for potential NEPI line extension and pipeline expansion, but it is too early to share additional details.